Key Finding
Moxa-combustion byproducts significantly improved spatial learning, memory, and olfactory function in Alzheimer's disease mice through olfactory-mediated modulation of the GSK-3β/CREB pathway, with effects disappearing after olfactory blockade.
Researchers investigated whether the smoke from burning moxa (an herb used in traditional Chinese medicine called moxibustion) could improve memory and cognitive problems in Alzheimer's disease by working through the sense of smell. Using a mouse model of Alzheimer's disease, scientists exposed animals to moxa smoke for 12 weeks and tested their memory, learning ability, and sense of smell. The study found that mice exposed to moxa smoke showed significant improvements in spatial learning and memory compared to untreated mice. Their sense of smell also improved, which is important because smell dysfunction is an early sign of Alzheimer's disease. When researchers examined brain tissue, they found that moxa smoke increased the number of healthy cells in both the olfactory bulb (the smell center of the brain) and the hippocampus (the memory center). The treatment also improved connections between brain cells and regulated important proteins involved in memory formation. Interestingly, when researchers blocked the mice's sense of smell using a chemical compound, the beneficial effects of moxa smoke disappeared, confirming that the treatment works through olfactory pathways. The mice also showed reduced anxiety and depression-like behaviors after treatment. This research suggests that moxibustion may help cognitive function in Alzheimer's disease patients by stimulating the olfactory system and supporting healthy brain cell communication. If you're considering moxibustion for cognitive concerns, seek treatment from a qualified, licensed acupuncturist trained in traditional moxibustion techniques.
This study examined whether moxa-combustion byproducts (MCB) improve cognition in Alzheimer's disease via olfactory-mediated GSK-3β/CREB pathway modulation. Four-month-old APP/PS1 transgenic mice (sample size not explicitly stated) received 12 weeks of MCB exposure. Behavioral testing (Morris water maze, buried food pellet test, open field test) demonstrated significant improvements in spatial learning, memory, and olfactory function. Histological analysis via HE staining revealed increased olfactory mitral cells and hippocampal CA1 neurons. TEM confirmed enhanced synaptic plasticity. Western blot analysis showed MCB downregulated GSK-3β while upregulating CREB and c-Fos in olfactory bulb and hippocampal tissues. Crucially, olfactory blockade with 3-methylindole abolished MCB's therapeutic effects, confirming olfactory-mediated mechanisms. MCB also reduced anxiety and depression-like behaviors. Clinical implications suggest moxibustion may benefit cognitive decline through olfactory system stimulation and modulation of synaptic plasticity pathways, supporting its use for neurodegenerative conditions with olfactory involvement.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Different moxibustion temperatures activate distinct thermosensitive proteins and pathways that influence the phenotypic remodeling of primary lesion cells in rheumatoid arthritis, including fibroblast-like synoviocytes, macrophages, and T cells.
📌 Moxibustion significantly reduced arthritis severity in animal models with large effect sizes (SMD -3.72 for arthritis index) while suppressing pro-inflammatory cytokines and key signaling pathways including NF-κB and NLRP3 inflammasome.
📌 Three transdermal moxibustion compounds—Citral, α-Terpineol, and Borneol—were identified as targeting TNF-α to reduce rheumatoid arthritis through MAPK pathway inhibition and MMP modulation.